VEGFA and neoplasm: TKI agents, such as sorafenib and lenvatinib are multitarget VEGF inhibitors that reduce angiogenesis and normalize abnormal vessels, facilitate the entry of cytotoxic agents into the tumor, and achieve higher concentrations.